Isongifolene Improves Crohn's Disease-Like Colitis in Mice by Reducing Apoptosis of Intestinal Epithelial Cells

DUAN Ting, GENG Zhijun, YANG Jingjing, YIN Lixia, SUN Mingxi, WANG Shunyin, ZHANG Xiaofeng, LI Jing, HU Jianguo,

Abstract

To investigate the effect and molecular mechanism of isolongifolene (ISO) on the apoptosis of intestinal epithelial cells and 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced Crohn's disease (CD)-like colitis in mice.

Methods 

In the animal experiments, mice were randomly assigned to the wild type (WT) group, TNBS group and TNBS+ISO group, with 8 mice in each group. Colitis models of mice were established in the TNBS group and the TNBS+ISO group by rectal injection of TNBS. After modeling, the mice in the TNBS+ISO group were given ISO intervention via intragastric gavage (10 mg/kg), and the other two groups were given the same amount of normal saline via intragastric gavage. The mice were sacrificed on the 7th day. The changes in body mass, disease activity scores (DAI), and the colon length of mice were measured, and transepithelial electrical resistance (TEER) of the colon tissues was determined. The score of colon inflammation was calculated according to HE staining. The levels of intestinal mucosal inflammatory factors, including tumor necrosis factor alpha (TNF-α), interferon (IFN)-γ, interleukin (IL)-1β, and IL-6, were measured by RT-PCR and ELISA. The apoptosis of colon tissue cells was determined by TUNEL assay. The expressions of apoptotic proteins (cleaved caspase-3/caspase-3 and Bax), an anti-apoptotic protein (Bcl-2), and tight junction proteins (ZO-1 and claudin-1) were detected by Western blot and immunofluorescence. In the cell experiment, TNF-α was used to induce intestinal epithelial cell Caco-2 apoptosis model, which was treated with ISO. Then, intervention with the AMPK inhibitor Compound C was given. TUNEL assay, Western blot assay, and immunofluorescence assay were performed to measure apoptosis and the expression of apoptosis proteins in the Caco-2 cells. Gene Ontology (GO) enrichment analysis was performed to predict the biological function of ISO. Then, the mechanism involved was verified by examination of the mice and Caco-2 cells. Western blot was performed to determine the expression levels of p-AMPK/AMPK and p-PGC1α in the colon tissues from the mice of different groups and Caco-2 cells. The apoptosis of the cells was determined by TUNEL assay.

Results 

According to the results of the animal experiment, ISO could alleviate experimental colitis and intestinal barrier dysfunction, leading to improvements in body mass loss, colon length shortening, DAI score, inflammatory rating, and TEER values (all P<0.05) in mice. Furthermore, ISO decreased the expression of pro-inflammatory factors TNF-α, IFN-γ, IL-1β, and IL-6 and increased the expression of the tight junction proteins ZO-1 and claudin-1 (all P<0.05). In the cell experiment, in a TNF-α-induced intestinal epithelial cell model, ISO was also found to protect intestinal barrier against damage. ISO reduced the proportion of apoptotic intestinal epithelial cells, reduced the expression of cleaved-caspase-3/caspase-3 and Bax, and upregulated the level of Bcl-2 (all P<0.05). GO enrichment predictive analysis showed that the role of ISO in improving CD-like enteritis might be associated with the negative regulation of apoptosis. Verification of the mechanism showed that the expression of p-AMPK and p-PGC1α in the mice colon tissue was significantly upregulated after ISO intervention (P<0.05). In contrast, the AMPK inhibitor Compound C increased the apoptosis rate of ISO-treated Caco-2 cells and decreased the relative expression levels of ZO-1 and claudin-1 (P<0.05).

Conclusion 

ISO reduces intestinal epithelial cell apoptosis at least in part by activating AMPK/PGC1α signaling pathway, thereby alleviating TNBS-induced intestinal barrier dysfunction and CD-like colitis in mice.

 

Keywords: Crohn's disease, Isolongifolene, Intestinal epithelial cell apoptosis, Intestinal barrier, AMPK/PGC1α


Full Text:

PDF


References


TORRES J, MEHANDRU S, COLOMBEL J F, et al. Crohn's disease. Lancet, 2017, 389(10080): 1741–1755. doi: 10.1016/S0140-6736(16)31711-1. VEAUTHIER B, HORNECKER J R. Crohn's disease: diagnosis and management. Am Fam Physician, 2018, 98(11): 661–669.

CHEN X M, LIU Y, HE Y S, et, al. Research progress of influencing factors of Crohn's disease pathogenesis. Modn Int Diagn Treat Gastroenterol, 2023, 28(7): 912–918. doi: 10.3969/j.issn.1672-2159.2023. 07.026.

RODA G, NG S C, KOTZE P G, et al. Crohn's disease. Nat Rev Dis Primers, 2020, 6(1): 22. doi: 10.1038/s41572-020-0156-2.

CAMILLERI M, MADSEN K, SPILLER R, et al. Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil, 2012, 24(6): 503–512. doi: 10.1111/j.1365-2982.2012.01921.x.

TURNER J R. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol, 2009, 9(11): 799–809. doi: 10.1038/nri2653.

GÜNTHER C, NEUMANN H, NEURATH M F, et al. Apoptosis, necrosis and necroptosis: cell death regulation in the intestinal epithelium. Gut, 2013, 62(7): 1062–1071. doi: 10.1136/gutjnl-2011-301364.

VERNIA F, VALVANO M, LONGO S, et al. Vitamin D in inflammatory bowel diseases. Mechanisms of action and therapeutic implications. Nutrients, 2022, 14(2): 269. doi: 10.3390/nu14020269.

ZHUANG X, CHEN B, HUANG S, et al. Hypermethylation of miR-145 promoter-mediated SOX9-CLDN8 pathway regulates intestinal mucosal barrier in Crohn's disease. EBioMedicine, 2022, 76: 103846. doi: 10.1016/j. ebiom.2022.103846.

ZHOU L, ZHU L, WU X, et al. Decreased TMIGD1 aggravates colitis and intestinal barrier dysfunction via the BANF1-NF-κB pathway in Crohn's disease. BMC Med, 2023, 21(1): 287. doi: 10.1186/s12916-023-02989-2.

YANG L, LUO H, TAN D, et al. A recent update on the use of Chinese medicine in the treatment of inflammatory bowel disease. Phytomedicine, 2021, 92: 153709. doi: 10.1016/j.phymed.2021.153709.

LI J, LI J, FANG H, et al. Isolongifolene alleviates liver ischemia/reperfusion injury by regulating AMPK-PGC1α signaling pathway-mediated inflammation, apoptosis, and oxidative stress. Int Immunopharmacol, 2022, 113(Pt A): 109185. doi: 10.1016/j.intimp.2022. 109185.

BALAKRISHNAN R, VIJAYRAJA D, MOHANKUMAR T, et al. Isolongifolene mitigates rotenone-induced dopamine depletion and motor deficits through anti-oxidative and anti-apoptotic effects in a rat model of Parkinson's disease. J Chem Neuroanat, 2021, 112: 101890. doi: 10.1016/j.jchemneu.2020.101890.

AMARASIRI S S, ATTANAYAKE A P, ARAWWAWALA L, et al. Nephroprotective activity of Vetiveria zizanioides (L.) Nash supplement in doxorubicin-induced nephrotoxicity model of Wistar rats. J Food Biochem, 2021, 45(9): e13901. doi: 10.1111/jfbc.13901.

PENG L, LI Z R, GREEN R S, et al. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr, 2009, 139(9): 1619–1625. doi: 10.3945/jn.109.104638.

ZHANG J, CEN L, ZHANG X, et al. MPST deficiency promotes intestinal epithelial cell apoptosis and aggravates inflammatory bowel disease via AKT. Redox Biol, 2022, 56: 102469. doi: 10.1016/j.redox.2022.102469. SPENCER D M, VELDMAN G M, BANERJEE S, et al. Distinct inflammatory mechanisms mediate early versus late colitis in mice. Gastroenterology, 2002, 122(1): 94–105. doi: 10.1053/gast.2002.30308.

MINTON K. Intestinal barrier protection. Nat Rev Immunol, 2022, 22(3): 144–145. doi: 10.1038/s41577-022-00685-5.

MEHANDRU S, COLOMBEL J F. The intestinal barrier, an arbitrator turned provocateur in IBD. Nat Rev Gastroenterol Hepatol, 2021, 18(2): 83–84. doi: 10.1038/s41575-020-00399-w.

OKUMURA R, TAKEDA K. Roles of intestinal epithelial cells in the maintenance of gut homeostasis. Exp Mol Med, 2017, 49(5): e338. doi: 10. 1038/emm.2017.20.

PATANKAR J V, BECKER C. Cell death in the gut epithelium and implications for chronic inflammation. Nat Rev Gastroenterol Hepatol, 2020, 17(9): 543–556. doi: 10.1038/s41575-020-0326-4.

HUAI M, ZENG J, GE W. Artemisinin ameliorates intestinal inflammation by skewing macrophages to the M2 phenotype and inhibiting epithelial-mesenchymal transition. Int Immunopharmacol, 2021, 91: 107284. doi: 10.1016/j.intimp.2020.107284.

LUO X, WANG X, HUANG S, et al. Paeoniflorin ameliorates experimental colitis by inhibiting gram-positive bacteria-dependent MDP-NOD2 pathway. Int Immunopharmacol, 2021, 90: 107224. doi: 10. 1016/j.intimp.2020.107224.

ZHANG D, ZHOU X, ZHANG K, et al. Glucomannan from Aloe vera gel maintains intestinal barrier integrity via mitigating anoikis mediated by Nrf2-mitochondria axis. Int J Biol Macromol, 2023, 235: 123803. doi: 10. 1016/j.ijbiomac.2023.123803.

FU Z W, WANG L X, GE H Y. Experimental study of the aloe polysaccharides relieving enteritis by regulating Th17/Treg cell balance. Chin Arch Gen Surg, 2019, 13(6): 435–440. doi: 10.3877/cma.j.issn.1674-0793.2019.06.004.


Refbacks

  • There are currently no refbacks.